Increased chemosensitivity and radiosensitivity of human breast cancer cell lines treated with novel functionalized single‑walled carbon nanotubes

Jia,Yijun; Weng,Ziyi; Wang,Chuanying; Zhu,Mingjie; Lu,Yunshu; Ding,Longlong; Wang,Yongkun; Cheng,Xianhua; Lin,Qing; Wu,Kejin

doi:10.3892/ol.2016.5402

Increased chemosensitivity and radiosensitivity of human breast cancer cell lines treated with novel functionalized single‑walled carbon nanotubes

Authors:
- Yijun Jia
- Ziyi Weng
- Chuanying Wang
- Mingjie Zhu
- Yunshu Lu
- Longlong Ding
- Yongkun Wang
- Xianhua Cheng
- Qing Lin
- Kejin Wu
View Affiliations

Affiliations: Department of General Surgery, XinHua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, P.R. China, Department of General Surgery, Shanghai International Medical Center, Shanghai 201318, P.R. China, School of Mechanical and Power Engineering, Shanghai Jiaotong University, Shanghai 200240, P.R. China, Department of Pathology, XinHua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, P.R. China, Department of Breast and Thyroid Surgery, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China, Department of Radiology, Tenth People's Hospital, Shanghai Tongji University School of Medicine, Shanghai 200072, P.R. China
Published online on: November 21, 2016 https://doi.org/10.3892/ol.2016.5402
Pages: 206-214
Copyright: © Jia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hypoxia is a major cause of treatment resistance in breast cancer. Single‑walled carbon nanotubes (SWCNTs) exhibit unique properties that make them promising candidates for breast cancer treatment. In the present study, a new functionalized single‑walled carbon nanotube carrying oxygen was synthesized; it was determined whether this material could increase chemosensitivity and radiosensitivity of human breast cancer cell lines, and the underlying mechanisms were investigated. MDA‑MB‑231 cells growing in folic acid (FA) free medium, MDA‑MB‑231 cells growing in medium containing FA and ZR‑75‑1 cells were treated with chemotherapy drugs or radiotherapy with or without tombarthite‑modified‑FA‑chitosan (R‑O2‑FA‑CHI)‑SWCNTs under hypoxic conditions, and the cell viability was determined by water‑soluble tetrazolium salts‑1 assay. The cell surviving fractions were determined by colony forming assay. Cell apoptosis induction was monitored by flow cytometry. Expression of B‑cell lymphoma 2 (Bcl‑2), survivin, hypoxia‑inducible factor 1‑α (HIF‑1α), multidrug resistance‑associated protein 1 (MRP‑1), P‑glycoprotein (P‑gp), RAD51 and Ku80 was monitored by western blotting. The novel synthesized R‑O2‑FA‑CHI‑SWCNTs were able to significantly enhance the chemosensitivity and radiosensitivity of human breast cancer cell lines and the material exhibited its expected function by downregulating the expression of Bcl‑2, survivin, HIF‑1α, P‑gp, MRP‑1, RAD51 and Ku80.

View Figures

View References

1	National Comprehensive Cancer Network (NCNN), . Breat cancerNCCN Clinical Practice Guidelines in Oncology. 3rd. NCNN; Fort Washington, PA, USA: 2013, PubMed/NCBI
2	Ward C, Langdon SP, Mullen P, Harris AL, Harrison DJ, Supuran CT and Kunkler IH: New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat Rev. 39:171–179. 2013. View Article : Google Scholar : PubMed/NCBI
3	Rademakers SE, Span PN, Kaanders JH, Sweep FC, van der Kogel AJ and Bussink J: Molecular aspects of tumour hypoxia. Mol Oncol. 2:41–53. 2008. View Article : Google Scholar : PubMed/NCBI
4	Vaupel P, Mayer A and Höckel M: Tumor hypoxia and malignant progression. Methods Enzymol. 381:335–354. 2004. View Article : Google Scholar : PubMed/NCBI
5	Rundqvist H and Johnson RS: Tumour oxygenation: Implications for breast cancer prognosis. J Intern Med. 274:105–112. 2013. View Article : Google Scholar : PubMed/NCBI
6	Trédan O, Galmarini CM, Patel K and Tannock IF: Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 99:1441–1454. 2007. View Article : Google Scholar : PubMed/NCBI
7	Vaupel P and Mayer A: Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev. 26:225–239. 2007. View Article : Google Scholar : PubMed/NCBI
8	Nordsmark M, Overgaard M and Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 41:31–39. 1996. View Article : Google Scholar : PubMed/NCBI
9	Denny WA: The role of hypoxia-activated prodrugs in cancer therapy. Lancet Oncol. 1:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
10	Guise CP, Mowday AM, Ashoorzadeh A, Yuan R, Lin WH, Wu DH, Smaill JB, Patterson AV and Ding K: Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. Chin J Cancer. 33:80–86. 2014. View Article : Google Scholar : PubMed/NCBI
11	Liapis V, Labrinidis A, Zinonos I, Hay S, Ponomarev V, Panagopoulos V, DeNichilo M, Ingman W, Atkins GJ, Findlay DM, et al: Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. Cancer Lett. 357:160–169. 2015. View Article : Google Scholar : PubMed/NCBI
12	Kimura H, Braun RD, Ong ET, Hsu R, Secomb TW, Papahadjopoulos D, Hong K and Dewhirst MW: Fluctuation in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 56:5522–5528. 1996.PubMed/NCBI
13	Bennett MH, Feldmeier J, Smee R and Milross C: Hyperbaric oxygenation for tumor sensitization to radiotherapy. Cochrane Database Syst Rev. 18:CD0050072012.
14	Overgaard J, Eriksen JG, Nordsmark M, Alsner J and Horsman MR: Danish Head and Neck Cancer Study Group: Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 6:757–764. 2005. View Article : Google Scholar : PubMed/NCBI
15	Xuhui Ma, Zhenjing Miao and Hongyun Wang: Some problems with hyperbaric oxygenation in treating cancers. Linchuang Junyi Zazhi. 38:862–864. 2010.
16	Williamson SK, Crowley JJ, Lara PN Jr, McCoy J, Lau DH, Tucker RW, Mills GM and Gandara DR: Southwest Oncology Group Trial S0003: Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol. 23:9097–9104. 2005. View Article : Google Scholar : PubMed/NCBI
17	Jevamohan P, Hasumura T, Nagaoka Y, Yoshida Y, Maekawa T and Kumar DS: Accelerated killing of cancer cells using a multifunctional single-walled carbon nanotube-based system for targeted drug delivery in combination with photothermal therapy. Int J Nanomedicine. 8:2653–2667. 2013.PubMed/NCBI
18	Das M, Datir SR, Singh RP and Jain S: Augmented anticancer activity of a targeted, intracellularly activatable, theranostic nanomedicine based on fluorescent and radiolabeled, methotrexate-folic Acid-multiwalled carbon nanotube conjugate. Mol Pharm. 10:2543–2557. 2013. View Article : Google Scholar : PubMed/NCBI
19	Lin Y, Taylor S, Li H, Fernando KA Shiral, Qu L, Wang W, Gu L, Zhou B and Sun Y: Advances toward bioapplications of carbon nanotubes. J Mater Chem. 14:527–541. 2004. View Article : Google Scholar
20	Bianco A, Kostarelos K and Prato M: Applications of carbon nanotubes in drug delivery. Curr Opin Chem Biol. 9:674–679. 2005. View Article : Google Scholar : PubMed/NCBI
21	Prato M, Kostarelos K and Bianco A: Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res. 41:60–68. 2008. View Article : Google Scholar : PubMed/NCBI
22	Xu J, Zhu MH, Liu JJ and Zhao Z: The state-of-art of researches on rare earth surface engineering and its tribological applications. China Surface Engineering. 1:20–23. 2001.
23	Sun ZY and Cheng XH: Friction/wear behaviors of rare earth treated carbon nanotubes/amino silane self-assembled composite film on silicon substrate. Tribology. 31:156–160. 2011.
24	Ravichandran P, Baluchamy S, Gopikrishnan R, Biradar S, Ramesh V, Goornavar V, Thomas R, Wilson BL, Jeffers R, Hall JC and Ramesh GT: Pulmonary biocompatibility assessment of inhaled single-wall and multiwall carbon nanotubes in BALB/c mice. J Biol Chem. 286:29725–29733. 2011. View Article : Google Scholar : PubMed/NCBI
25	Lam CW, James JT, McCluskey R, Arepalli S and Hunter RL: A review of carbon nanotube toxicity and assessment of potential occupational and environmental health risks. Crit Rev Toxicol. 36:189–217. 2006. View Article : Google Scholar : PubMed/NCBI
26	Wang Y, Lin Q, Wu K, Zhu M, Lu Y, Chen J, Huang S, Cheng X and Weng Z: Experimental study of bio-security of functionalized single-walled and multi-walled carbon nanotubes. Nano Biomed Eng. 3:249–255. 2011. View Article : Google Scholar
27	Eccles SA, Aboaqye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, et al: Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 15:R922013. View Article : Google Scholar : PubMed/NCBI
28	Gray LH, Conger AD, Ebert M, Hornsey S and Scott OC: The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 26:638–648. 1953. View Article : Google Scholar : PubMed/NCBI
29	Bush RS, Jenkin RD, Allt WE, Beale FA, Bean H, Dembo AJ and Pringle JF: Definitive evidence for hypoxic cells influence in the cure in cancer therapy. Br J Cancer Suppl. 3:302–306. 1978.PubMed/NCBI
30	Brown JM: Evidence for acutely hypoxic cells in mouse tumor, and a possible mechanism of reoxygenation. Br J Radiol. 52:650–656. 1979. View Article : Google Scholar : PubMed/NCBI
31	Tan A, Yildirimer L, Rajadas J, De La Peña H, Pastorin G and Seifalian A: Quantum dots and carbon nanotubes in oncology: A review on emerging theranostic applications in nanomedicine. Nanomedicine (Lond). 6:1101–1114. 2016. View Article : Google Scholar
32	Bregoli L, Movia D, Gavigan-Imedio JD, Lysaght J, Reynolds J and Prina-Mello A: Nanomedicine applied to translational oncology: A future perspective on cancer treatment. Nanomedicine. 12:81–103. 2015.PubMed/NCBI
33	Herreros E, Morales S, Cortés C, Cabaña M, Peñaloza JP, Jara L, Geraldo D, Otero C and Fernández-Ramires R: Advances in nanomedicine towards clinical application in oncology and immunology. Curr Pharm Biotechnol. 15:864–879. 2014. View Article : Google Scholar : PubMed/NCBI
34	Joshi P, Chakraborti S, Ramirez-Vick JE, Ansari ZA, Shanker V, Chakrabarti P and Singh SP: The anticancer activity of chloroquine-gold nanoparticles against MCF-7 breast cancer cells. Colloids Surf B Biointerfaces. 95:195–200. 2012. View Article : Google Scholar : PubMed/NCBI
35	Wang H, Li F, Du C, Wang H, Mahato RI and Huang Y: Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer. Mol Pharm. 11:2600–2611. 2014. View Article : Google Scholar : PubMed/NCBI
36	Leamon CP and Reddy JA: Folate-targeted chemotherapy. Drug Deliv Rev. 56:1127–1141. 2004. View Article : Google Scholar
37	Sudimack J and Lee RJ: Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 41:147–162. 2000. View Article : Google Scholar : PubMed/NCBI
38	Low PS and Kularatne SA: Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 13:256–262. 2009. View Article : Google Scholar : PubMed/NCBI
39	Wang S and Low PS: Folate-mediated targeting antineoplastic drugs, imaging agents and nucleic acids to cancer cells. J Control Release. 53:39–48. 1998. View Article : Google Scholar : PubMed/NCBI
40	Cheng X: A preparation method of rare earth modified-folic acid-chitosan-SWCNTs. China Patent 103,007,285. Filed July 20, 2012; issued. November 24–2012
41	Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE and Oltvai ZN: Bcl-2/Bax: A rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol. 4:327–25332. 1993.PubMed/NCBI
42	Lindsay J, Esposti MD and Gilmore AP: Bcl-2 proteins and mitochondria-specificity in membrane targeting for death. Biochim Biophys Acta. 1813:532–539. 2001. View Article : Google Scholar
43	Chinnaiyan AM, Orth K, O'Rourke K, Duan H, Poirier GG and Dixit VM: Molecular ordering of the cell death pathway. Bcl-2 and Bcl-xL function upstream of the CED-3-like apoptotic proteases. J Biol Chem. 271:4573–4576. 1996.PubMed/NCBI
44	Kitanaka C, Namiki T, Noguchi K, Mochizuki T, Kagaya S, Chi S, Hayashi A, Asai A, Tsujimoto Y and Kuchino Y: Caspase-dependent apoptosis of COS-7 cells induced by Bax overexpression: Differential effects of Bcl-2 and Bcl-xL on Bax-induced caspase activation and apoptosis. Oncogene. 15:1763–1772. 1997. View Article : Google Scholar : PubMed/NCBI
45	Shiu LY, Chang LC, Liang CH, Huang YS, Sheu HM and Kuo KW: Solamargine induces apoptosis and sensitizes breast cancer cells to cisplatin. Food Chem Toxicol. 45:2155–2164. 2007. View Article : Google Scholar : PubMed/NCBI
46	de Moraes G Nestal, Vasconcelos FC, Delbue D, Mognol GP, Sternberg C, Viola JP and Maia RC: Doxorubicin induces cell death in breast cancer cells regardless of survivin and XIAP expression levels. Eur J Cell Biol. 92:247–256. 2013. View Article : Google Scholar : PubMed/NCBI
47	Lee JW, Bae SH, Jeong JW, Kim SH and Kim KW: Hypoxia-inducible factor (HIF-1) alpha: Its protein stability and biological functions. Exp Mol Med. 36:1–12. 2004. View Article : Google Scholar : PubMed/NCBI
48	Choi KS, Bae MK, Jeong JW, Moon HE and Kim KW: Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol. 36:120–127. 2003.PubMed/NCBI
49	Powell S and McMillan TJ: DNA damage and repair following treatment with ionizing radiation. Radiother Oncol. 19:95–108. 1990. View Article : Google Scholar : PubMed/NCBI
50	Santivasi WL and Xia F: Ionizing radiation-induced DNA damage, response, and repair. Antioxid Redox Signal. 21:251–259. 2014. View Article : Google Scholar : PubMed/NCBI
51	Bryant PE: Repair and chromosomal damage. Radiother Oncol. 72:251–256. 2004. View Article : Google Scholar : PubMed/NCBI
52	Kavanagh JN, Redmond KM, Schettino G and Prise KM: DNA double strand break repair: A radiation perspective. Antioxid Redox Signal. 18:2458–2472. 2013. View Article : Google Scholar : PubMed/NCBI
53	Deschner EE and Gray LH: Influence of oxygen tension on x-ray-induced chromosomal damage in Ehrlich ascites tumor cells irradiated in vitro and in vivo. Radiat Res. 11:115–146. 1959. View Article : Google Scholar : PubMed/NCBI
54	Gray LH, Conger AD, Ebert M, Hornsey S and Scott OC: The concentration of oxygen dissolved in tissue at the time of irradiation as a factor in radiotherapy. Br J Radiol. 26:638–648. 1953. View Article : Google Scholar : PubMed/NCBI
55	Choudhury A, Cuddihy A and Bristow RG: Radiation and new molecular agents part 1: Targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol. 16:51–58. 2006. View Article : Google Scholar : PubMed/NCBI
56	Lieber MR: The mechanism of human nonhomologous DNA end joining. J Biol Chem,. 283:1–5. 2008. View Article : Google Scholar